6533b82afe1ef96bd128b60b

RESEARCH PRODUCT

99mTechnetium-Mercaptoacetyltriglycin (MAG3) zum Nachweis von Nierenveränderungen nach extrakorporaler Stoßwellenlithotripsie

U. WitschH. El-damanhouryB. Nägele-wöhrleT. SchaubK. Hahn

subject

medicine.medical_specialtyKidneybusiness.industrymedicine.medical_treatmentUrinary systemUrologychemistry.chemical_elementRenal functionLithotripsyTechnetiumExtracorporeal shock wave lithotripsyTechnetium Tc 99m Mertiatidemedicine.anatomical_structurechemistrymedicineRadiology Nuclear Medicine and imagingbusinessProspective cohort study

description

Extracorporeal shock wave lithotripsy (ESWL) has become the treatment of choice for urinary calculi. 117 patients were studied prospectively with 99mTc mercaptoacetyltriglycine (MAG3) before and after ESWL. 79 (66%) of the 119 kidneys treated had abnormal findings. Of these 63/119 (53%) had abnormal scans. 41 (65%) had focal lesions with a delayed intrarenal transport. The remaining 22 had a diffuse delay of intrarenal transport. A loss of relative renal function of 3% and more compared to the pretreatment values was observed in 50/119 (42%) patients. 99mTc MAG3 should be done routinely together with radiologic tests (CT or MRI) before and after ESWL to select the patients at risk for post ESWL hypertension.

yearjournalcountryeditionlanguage
1992-10-01RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
https://doi.org/10.1055/s-2008-1033019